144 related articles for article (PubMed ID: 33168965)
1. Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test.
Vigneswaran HT; Palsdottir T; Olsson H; Haug ES; Picker W; Löffeler S; Grönberg H; Eklund M; Nordström T
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):457-464. PubMed ID: 33168965
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.
Grönberg H; Eklund M; Picker W; Aly M; Jäderling F; Adolfsson J; Landquist M; Haug ES; Ström P; Carlsson S; Nordström T
Eur Urol; 2018 Dec; 74(6):722-728. PubMed ID: 30001824
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
4. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
[TBL] [Abstract][Full Text] [Related]
5. A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging.
Palsdottir T; Nordström T; Aly M; Jäderling F; Clements M; Grönberg H; Eklund M
Eur Urol Oncol; 2019 Sep; 2(5):490-496. PubMed ID: 31412016
[TBL] [Abstract][Full Text] [Related]
6. External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.
Palsdottir T; Grönberg H; Hilmisson A; Eklund M; Nordström T; Vigneswaran HT
Eur Urol Focus; 2023 May; 9(3):455-462. PubMed ID: 36522257
[TBL] [Abstract][Full Text] [Related]
7. Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS).
Olsson H; Nordström T; Jäderling F; Egevad L; Vigneswaran HT; Annerstedt M; Grönberg H; Eklund M; Lantz A
J Natl Cancer Inst; 2021 May; 113(5):632-640. PubMed ID: 32866231
[TBL] [Abstract][Full Text] [Related]
8. The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort.
Möller A; Olsson H; Grönberg H; Eklund M; Aly M; Nordström T
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):137-142. PubMed ID: 30171228
[TBL] [Abstract][Full Text] [Related]
9. Prostate Biopsies Can Be Omitted in Most Patients with a Positive Stockholm3 Test and Negative Prostate Magnetic Resonance Imaging.
Vinje CA; Vigmostad MN; Kjosavik SR; Grönberg H; Gilje B; Skeie S
Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37805292
[TBL] [Abstract][Full Text] [Related]
10. Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE).
Klotz L; Chin J; Black PC; Finelli A; Anidjar M; Machado A; Levental M; Ghai S; Chang SD; Patel C; Kassam Z; Loblaw A; Kebabdjian M; Pond G; Haider MA
Eur Urol Oncol; 2024 Jun; 7(3):456-461. PubMed ID: 37838556
[TBL] [Abstract][Full Text] [Related]
11. A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study.
Waldén M; Aldrimer M; Lagerlöf JH; Eklund M; Grönberg H; Nordström T; Palsdottir T
Eur Urol Open Sci; 2022 Apr; 38():32-39. PubMed ID: 35495282
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study.
Hao S; Heintz E; Östensson E; Discacciati A; Jäderling F; Grönberg H; Eklund M; Nordström T; Clements MS
Eur Urol; 2022 Jul; 82(1):12-19. PubMed ID: 35094896
[TBL] [Abstract][Full Text] [Related]
13. Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms.
Nordström T; Engel JC; Bergman M; Egevad L; Aly M; Eklund M; Palsdottir T; Grönberg H
Eur Urol Open Sci; 2021 Feb; 24():11-16. PubMed ID: 34337490
[TBL] [Abstract][Full Text] [Related]
14. Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI.
Nordström T; Jäderling F; Carlsson S; Aly M; Grönberg H; Eklund M
BMJ Open; 2019 Jun; 9(6):e027816. PubMed ID: 31201191
[TBL] [Abstract][Full Text] [Related]
15. Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.
Klotz L; Loblaw A; Sugar L; Moussa M; Berman DM; Van der Kwast T; Vesprini D; Milot L; Kebabdjian M; Fleshner N; Ghai S; Chin J; Pond GR; Haider M
Eur Urol; 2019 Feb; 75(2):300-309. PubMed ID: 30017404
[TBL] [Abstract][Full Text] [Related]
16. MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort.
Luzzago S; de Cobelli O; Mistretta FA; Piccinelli ML; Lorusso V; Morelli M; Bianchi R; Catellani M; Cozzi G; Di Trapani E; Pricolo P; Alessi S; Ferro M; Marvaso G; Matei DV; Jereczek-Fossa BA; Petralia G; Musi G
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):406-413. PubMed ID: 32989259
[TBL] [Abstract][Full Text] [Related]
17. Using decision curve analysis to benchmark performance of a magnetic resonance imaging-based deep learning model for prostate cancer risk assessment.
Deniffel D; Abraham N; Namdar K; Dong X; Salinas E; Milot L; Khalvati F; Haider MA
Eur Radiol; 2020 Dec; 30(12):6867-6876. PubMed ID: 32591889
[TBL] [Abstract][Full Text] [Related]
18. Ethnic variation in prostate cancer detection: a feasibility study for use of the Stockholm3 test in a multiethnic U.S. cohort.
Vigneswaran HT; Discacciati A; Gann PH; Grönberg H; Eklund M; Abern MR
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):120-127. PubMed ID: 32641739
[TBL] [Abstract][Full Text] [Related]
19. An Evaluation of Screening Pathways Using a Combination of Magnetic Resonance Imaging and Prostate-specific Antigen: Results from the IP1-PROSTAGRAM Study.
Eldred-Evans D; Tam H; Sokhi H; Padhani AR; Connor M; Price D; Gammon M; Klimowska-Nassar N; Burak P; Day E; Winkler M; Fiorentino F; Ahmed HU
Eur Urol Oncol; 2023 Jun; 6(3):295-302. PubMed ID: 37080821
[TBL] [Abstract][Full Text] [Related]
20. Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer.
Deniffel D; Healy GM; Dong X; Ghai S; Salinas-Miranda E; Fleshner N; Hamilton R; Kulkarni G; Toi A; van der Kwast T; Zlotta A; Finelli A; Perlis N; Haider MA
Radiology; 2021 Aug; 300(2):369-379. PubMed ID: 34032510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
